• Pneumonias and Nosocomial Pneumonias
• Urinary Tract Infections
• Intra-abdominal Infections
• Gynaecological Infections, such as endometritis.
• Skin and Skin Structure Infections
• Cystic fibrosis and chronic lower respiratory tract infections
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion, with the effect of increasing the elimination half-life and plasma concentration of meropenem. As the potency and duration of action of Meropenem dosed without probenecid are adequate, the co-administration of probenecid with Meropenem is not recommended. Meropenem may reduce serum valproic acid levels. Subtherapeutic levels may be reached in some patients. Meropenem has been administered concomitantly with other medications without adverse pharmacological interactions